KLK6 and Alzheimer disease: To address these issues, we used a previously developed and validated quantification method to quantify CSF and plasma levels of KLK6 in a cross-sectional study of older patients with AD with a more advanced disease stage and a longitudinally followed cohort including patients with amnestic MCI and patients with sporadic AD with disease onset before and after 65 years of age.